The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

Seema A. Bhat, MD, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial.

Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.

Seema A. Bhat, MD, spotlights the advances that have been made with BTK inhibitors in chronic lymphocytic leukemia, shares emerging approaches under exploration, and forecasts where the field is headed.

Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

Seema A. Bhat, MD, discusses the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in young patients with treatment-naïve CLL.

Seema A. Bhat, MD, hematologist, discusses the role of targeted therapies in chronic lymphocytic leukemia.

Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.

Kami J. Maddocks, MD, discusses remaining challenges in treating patients with follicular lymphoma.

Kami J. Maddocks, MD, discusses unanswered questions with BTK inhibitors in B-cell malignancies.

Kami J. Maddocks, MD, discusses the tolerability and promise of tafasitamab in combination with lenalidomide in relapsed or refractory DLBCL.

Jennifer Woyach, MD, discusses clinical trials examining novel triplet regimens in chronic lymphocytic leukemia.

Kami J. Maddocks, MD, discusses the role of tazemetostat in patients with EZH2-mutant follicular lymphoma.

Jennifer Woyach, MD, discusses the safety profile of acalabrutinib compared with ibrutinib in chronic lymphocytic leukemia.

Jennifer Woyach, MD, discusses the role of acalabrutinib in chronic lymphocytic leukemia.

Kami J. Maddocks, MD, discusses the utility of BTK inhibitors in B-cell malignancies, challenges that are still faced in the space, and areas primed for additional development.

Jennifer Woyach, MD, discusses remaining sequencing questions within the field of chronic lymphocytic leukemia.

David O'Malley, MD, discusses the adverse effects associated with mirvetuximab soravtansine in ovarian cancer.

Kami J. Maddocks, MD, discusses emerging therapies in follicular lymphoma.

Jennifer Woyach, MD, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia.

Kami J. Maddocks, MD, discusses the clinical implications of the approval of tafasitamab and lenalidomide in relapsed/refractory DLBCL, as well as remaining challenges that future research efforts should address.

Jennifer Woyach, MD, discusses ​the role of chemoimmunotherapy in chronic lymphocytic leukemia.

David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

Gregory A. Otterson, MD, discusses data examining immunotherapy alone versus in combination in non–small cell lung cancer.

Jonathan E. Brammer, MD, discusses data that have been reported with inotuzumab ozogamicin (Besponsa) in acute lymphoblastic leukemia (ALL).

Alice S. Mims, MD, discusses the Beat AML Master Trial in acute myeloid leukemia (AML).

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.